Administration of Denosumab Preserves Bone Mineral Density at the Knee in Persons With Subacute Spinal Cord Injury: Findings From a Randomized Clinical Trial
- PMID: 33134767
- PMCID: PMC7587457
- DOI: 10.1002/jbm4.10375
Administration of Denosumab Preserves Bone Mineral Density at the Knee in Persons With Subacute Spinal Cord Injury: Findings From a Randomized Clinical Trial
Abstract
Persons with neurologically motor-complete spinal cord injury (SCI) have a marked loss of bone mineral density (BMD) of the long bones of the lower extremities, predisposing them to fragility fractures, especially at the knee. Denosumab, a commercially available human monoclonal IgG antibody to receptor activator of nuclear factor-κB ligand (RANKL), may provide an immunopharmacological solution to the rapid progressive deterioration of sublesional bone after SCI. Twenty-six SCI participants with subacute motor-complete SCI were randomized to receive either denosumab (60 mg) or placebo at baseline (BL), 6, and 12 months. Areal bone mineral density (aBMD) by dual energy x-ray absorptiometry (DXA) at 18 months at the distal femur was the primary outcome and aBMD of the proximal tibia and hip were the secondary outcomes analyzed in 18 of the 26 participants (denosumab, n = 10 and placebo, n = 8). The metrics of peripheral QCT (pQCT) were the exploratory outcomes analyzed in a subsample of the cohort (denosumab, n = 7 and placebo n = 7). The mean aBMD (±95% CI) for the denosumab versus the placebo groups demonstrated a significant group × time interactions for the following regions of interest at BL and 18 months: distal femoral metaphysis = mean aBMD 1.187; 95% CI, 1.074 to 1.300 and mean aBMD 1.202; 95% CI, 1.074 to 1.329 versus mean aBMD 1.162; 95% CI, 0.962 to 1.362 and mean aBMD 0.961; 95% CI, 0.763 to 1.159, respectively (p < 0.001); distal femoral epiphysis = mean aBMD 1.557; 95% CI, 1.437 to 1.675 and mean aBMD 1.570; 95% CI, 1.440 to 1.700 versus mean aBMD 1.565; 95% CI, 1.434 to 1.696 and mean aBMD 1.103; 95% CI, 0.898 to 1.309, respectively (p = 0.002); and proximal tibial epiphysis = mean aBMD 1.071; 95% CI, 0.957 to 1.186 and mean aBMD 1.050; 95% CI, 0.932 to 1.168 versus mean aBMD 0.994; 95% CI, 0.879 to 1.109 and mean aBMD 0.760; 95% CI, 0.601 to 0.919, respectively (p < 0.001). Analysis of pQCT imaging revealed a continued trend toward significantly greater loss in total volumetric BMD (vBMD) and trabecular vBMD at the 4% distal tibia region, with a significant percent loss for total bone mineral content. Thus, at 18 months after acute SCI, our findings show that denosumab maintained aBMD at the knee region, the site of greatest clinical relevance in the SCI population. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
Keywords: BONE MINERAL DENSITY; DENOSUMAB; DUAL ENERGY X‐RAY ABSORPTIOMETRY; IMMOBILIZATION OSTEOPOROSIS; PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY; SPINAL CORD INJURY.
© 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
Figures
Similar articles
-
Exploring the determinants of fracture risk among individuals with spinal cord injury.Osteoporos Int. 2014 Jan;25(1):177-85. doi: 10.1007/s00198-013-2419-1. Epub 2013 Jun 28. Osteoporos Int. 2014. PMID: 23812595 Free PMC article.
-
Progressive Sublesional Bone Loss Extends into the Second Decade After Spinal Cord Injury.J Clin Densitom. 2019 Apr-Jun;22(2):185-194. doi: 10.1016/j.jocd.2018.10.006. Epub 2018 Oct 31. J Clin Densitom. 2019. PMID: 30503961
-
Trabecular bone microarchitecture is deteriorated in men with spinal cord injury.J Bone Miner Res. 2004 Jan;19(1):48-55. doi: 10.1359/JBMR.0301208. J Bone Miner Res. 2004. PMID: 14753736
-
Bone loss at the distal femur and proximal tibia in persons with spinal cord injury: imaging approaches, risk of fracture, and potential treatment options.Osteoporos Int. 2017 Mar;28(3):747-765. doi: 10.1007/s00198-016-3798-x. Epub 2016 Dec 5. Osteoporos Int. 2017. PMID: 27921146 Review.
-
A Primary Care Provider's Guide to Bone Health in Spinal Cord-Related Paralysis.Top Spinal Cord Inj Rehabil. 2020 Spring;26(2):128-133. doi: 10.46292/sci2602-128. Top Spinal Cord Inj Rehabil. 2020. PMID: 32760192 Free PMC article. Review.
Cited by 2 articles
-
The Effects of Exercise and Activity-Based Physical Therapy on Bone after Spinal Cord Injury.Int J Mol Sci. 2022 Jan 6;23(2):608. doi: 10.3390/ijms23020608. Int J Mol Sci. 2022. PMID: 35054791 Free PMC article. Review.
-
Disuse Osteoporosis: Clinical and Mechanistic Insights.Calcif Tissue Int. 2021 Mar 18. doi: 10.1007/s00223-021-00836-1. Online ahead of print. Calcif Tissue Int. 2021. PMID: 33738515 Review.
References
-
- Biering‐Sorensen F, Bohr HH, Schaadt OP. Longitudinal study of bone mineral content in the lumbar spine, the forearm and the lower extremities after spinal cord injury. Eur J Clin Invest. 1990. Jun;20(3):330–5. - PubMed
-
- Eser P, Frotzler A, Zehnder Y, et al. Relationship between the duration of paralysis and bone structure: a pQCT study of spinal cord injured individuals. Bone. 2004. May;34(5):869–80. - PubMed
-
- Bauman WA, Wecht JM, Kirshblum S, et al. Effect of pamidronate administration on bone in patients with acute spinal cord injury. J Rehabil Res Dev. 2005. May–Jun;42(3):305–13. - PubMed
-
- Bauman WA, Cirnigliaro CM, La Fountaine MF, Martinez L, Kirshblum SC, Spungen AM. Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study. J Bone Miner Metab. 2015. Jul;33(4):410–21. - PubMed
-
- Shapiro J, Smith B, Beck T, et al. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int. 2007. May;80(5):316–22. - PubMed
LinkOut - more resources
Full Text Sources